Akebia Therapeutics Inc (NAS:AKBA)
$ 1.705 0.08 (4.91%) Market Cap: 358.54 Mil Enterprise Value: 352.78 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Akebia Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 12:30PM GMT
Release Date Price: $1.28 (+6.67%)
Claire Duffy
Jefferies - Analyst

Hey, everyone. My name is Claire, and I'm with the Jefferies Investment Banking Team. Welcome to the Jefferies Global Healthcare Conference. And it is my great pleasure to introduce John Butler, CEO of Akebia Therapeutics.

And with that, I'll hand it over to him.

John Butler
Akebia Therapeutics, Inc. - President and CEO

Thank you, Claire. Thanks so much for the invitation, and thanks, everyone, for joining us this morning. I'm excited to talk to you about Akebia Therapeutics.

I just want to remind you that I'm going to be making forward-looking statements, so please refer to our SEC filings for more information.

I actually really am very excited to talk to you about Akebia this morning. Just over a week ago, we had an incredibly important moment where the FDA responded to our dispute resolution around the CRL for vadadustat and gave us a clear path forward. This is an incredibly important moment for the company, one that really changes our trajectory. And I look forward to spending a fair amount

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot